Difference between revisions of "Drug index"
Jump to navigation
Jump to search
m (→Miscellaneous) |
|||
| Line 759: | Line 759: | ||
*[[:Category:WHO_Essential_Cancer_Medicine|WHO Essential Cancer Medicines]] | *[[:Category:WHO_Essential_Cancer_Medicine|WHO Essential Cancer Medicines]] | ||
| − | ==Medications by | + | ==Medications by Condition== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
| Line 815: | Line 815: | ||
*[[:Category:Penile cancer medications |Penile cancer medications]] | *[[:Category:Penile cancer medications |Penile cancer medications]] | ||
*[[:Category:Peripheral T-cell lymphoma medications|Peripheral T-cell lymphoma medications]] | *[[:Category:Peripheral T-cell lymphoma medications|Peripheral T-cell lymphoma medications]] | ||
| + | *[[:Category:Plasma cell leukemia medications|Plasma cell leukemia medications]] | ||
*[[:Category:Polycythemia vera medications|Polycythemia vera medications]] | *[[:Category:Polycythemia vera medications|Polycythemia vera medications]] | ||
*[[:Category:Primary mediastinal B-cell lymphoma medications|Primary mediastinal B-cell lymphoma medications]] | *[[:Category:Primary mediastinal B-cell lymphoma medications|Primary mediastinal B-cell lymphoma medications]] | ||
| Line 821: | Line 822: | ||
*[[:Category:Renal cancer medications|Renal cancer medications]] | *[[:Category:Renal cancer medications|Renal cancer medications]] | ||
*[[:Category:Sarcoma medications |Sarcoma medications]] | *[[:Category:Sarcoma medications |Sarcoma medications]] | ||
| + | *[[:Category:Sickle cell anemia medications|Sickle cell anemia medications]] | ||
*[[:Category:Small cell lung cancer medications|Small cell lung cancer medications]] | *[[:Category:Small cell lung cancer medications|Small cell lung cancer medications]] | ||
*[[:Category:T-cell lymphoma medications|T-cell lymphoma medications]] | *[[:Category:T-cell lymphoma medications|T-cell lymphoma medications]] | ||
Revision as of 18:35, 13 June 2016
Alphabetically
A
| back to top |
- Abemaciclib (LY2835219) in clinical trials
- Abexinostat (PCI-24781) in clinical trials
- Abiraterone (Zytiga)
- Acalabrutinib (ACP-196) in clinical trials
- Acetaminophen (Tylenol)
- Actinium-225 (225Ac)-Lintuzumab (Actimab-A) in clinical trials
- Acyclovir (Zovirax)
- Adenovirus-interferon-γ (TG1042) in clinical trials
- Ado-trastuzumab emtansine (Kadcyla)
- Afatinib (Gliotrif)
- Afuresertib (GSK2110183) in clinical trials
- AG-120 in clinical trials
- AG-221 in clinical trials
- Aldesleukin (Proleukin)
- Alectinib (Alecensa) FDA approved 12/11/2015
- Alemtuzumab (Campath)
- Alendronate (Fosamax)
- Alisertib (MLN8237) in clinical trials
- All-trans retinoic acid (ATRA)
- Allopurinol (Zyloprim)
- Altretamine (Hexalen)
- Alvocidib (Flavopiridol)
- Amatuximab (MORAb-009) in clinical trials
- AMG 330 in clinical trials
- Amifostine (Ethyol)
- Aminocaproic acid (Amicar)
- Aminoglutethimide (Cytadren)
- Amonafide (Quinamed) in clinical trials
- Amrubicin (Calsed)
- Amsacrine (Amsidine)
- Anagrelide (Agrylin)
- Anastrozole (Arimidex)
- Ancestim (Stemgen)
- Andexanet alfa (PRT4445)
- Anti-inhibitor coagulant complex (FEIBA NF)
- Antithrombin III (human and recombinant)
- Antithymocyte globulin, horse ATG (Atgam)
- Antithymocyte globulin, rabbit ATG (Thymoglobulin)
- Apixaban (Eliquis)
- Apocept (APG101) in clinical trials
- Aprepitant (Emend)
- Argatroban (Acova)
- ARN-509 in clinical trials
- Arsenic trioxide (Trisenox)
- Ascorbic acid (Vitamin C)
- Asparaginase (Elspar) discontinued
- Asparaginase Erwinia chrysanthemi (Erwinaze)
- Aspirin
- Astuprotimut-R (GSK1572932A) in clinical trials
- Atezolizumab (Tecentriq) FDA approved 5/18/2016
- Atovaquone (Mepron)
- Avatrombopag (E5501) in clinical trials
- Axitinib (Inlyta)
- Azacitidine (Vidaza)
B
| back to top |
- Bacillus Calmette-Guerin (BCG)
- Barasertib (AZD1152) in clinical trials
- Bavituximab (PGN401) in clinical trials
- Belagenpumatucel-L (Lucanix) in clinical trials
- Belinostat (Beleodaq)
- Bendamustine
- Betrixaban (PRT-054021) in clinical trials
- Bevacizumab (Avastin)
- Bexarotene (Targretin)
- Bicalutamide (Casodex)
- Binimetinib (MEK162) in clinical trials
- Bivalirudin (Angiomax)
- BHQ880 in clinical trials
- BL22 immunotoxin (CAT-3888) in clinical trials
- Bleomycin (Blenoxane)
- Blinatumomab (Blincyto)
- Bortezomib (Velcade)
- Bosutinib (Bosulif)
- Brentuximab vedotin (Adcetris)
- Brigatinib (AP26113) in clinical trials
- Buparlisib (BKM120) in clinical trials
- Busulfan (Myleran)
C
| back to top |
- Cabazitaxel (Jevtana)
- Cabozantinib (Cabometyx) FDA approved 4/25/2016
- Cabozantinib (Cometriq)
- Calcium phosphate rinse (Caphosol)
- Capecitabine (Xeloda)
- Caplacizumab in clinical trials
- Carboplatin (Paraplatin)
- Carfilzomib (Kyprolis)
- Carmustine (BiCNU)
- Carmustine wafer, polifeprosan 20 (Gliadel)
- Catumaxomab (Removab) in US clinical trials
- CC-292 (AVL-292) in clinical trials
- Ceritinib (Zykadia)
- Cetirizine (Zyrtec)
- Cetuximab (Erbitux)
- Chidamide (Epidaza)
- Chlorambucil (Leukeran)
- Chlorpheniramine (Chlor-Trimeton)
- Cimetidine (Tagamet)
- Cisplatin (Platinol)
- Cixutumumab (IMC-A12) in clinical trials
- Cladribine (Leustatin)
- Clarithromycin (Biaxin)
- Clemastine (Tavist)
- Clodronate (Bonefos)
- Clofarabine (Clolar)
- Clopidogrel (Plavix)
- Cobimetinib (Cotellic) FDA approved 11/10/2015
- Coltuximab ravtansine (CoR, SAR3419) in clinical trials
- Copanlisib (BAY 80-6946) in clinical trials
- CPX-351 in clinical trials
- Crenolanib (CP-868,596) in clinical trials
- Crizotinib (Xalkori)
- CTL019 in clinical trials
- Custirsen (OGX-011) in clinical trials
- Cyanocobalamin (Vitamin B12)
- Cyclophosphamide (Cytoxan)
- Cyclosporine modified (Neoral)
- Cyclosporine non-modified (Sandimmune)
- Cytarabine (Cytosar)
- Cytarabine liposomal (DepoCyt)
- Cytomegalovirus (CMV) Human Immunoglobulin (Cytogam)
D
| back to top |
- Dabigatran (Pradaxa)
- Dabrafenib (Tafinlar)
- Dacarbazine (DTIC)
- Dacomitinib (PF-00299804) in clinical trials
- Dactinomycin (Cosmegen)
- Dalteparin (Fragmin)
- Dapsone (Aczone)
- Daratumumab (Darzalex) FDA approved 11/16/2015
- Darbepoetin alfa (Aranesp)
- Dasatinib (Sprycel)
- Daunorubicin (Cerubidine)
- Daunorubicin liposomal (DaunoXome)
- Decitabine (Dacogen)
- Deferasirox (Exjade)
- Deferasirox (Jadenu) FDA approved 3/30/2015
- Deferiprone (Ferriprox)
- Deferoxamine (Desferal)
- Defibrotide (Defitelio) FDA approved 3/30/2016
- Degarelix (Firmagon)
- Denileukin diftitox (Ontak)
- Denosumab (Xgeva)
- Desmopressin (DDAVP)
- Dexamethasone (Decadron)
- Dexrazoxane (Zinecard)
- Diethylstilbestrol (DES)
- Dinaciclib (SCH 727965) in clinical trials
- Dinutuximab (Unituxin) FDA approved 3/10/2015
- Diphenhydramine (Benadryl)
- Discodermolide (XAA296) in clinical trials
- DMUC5754A in clinical trials
- Docetaxel (Taxotere)
- Docusate (Colace)
- Dolasetron (Anzemet)
- Dovitinib (TKI-258) in clinical trials
- Doxorubicin (Adriamycin)
- Doxorubicin liposomal (Doxil)
- Dutasteride (Avodart)
- Duvelisib (IPI-145) in clinical trials
E
| back to top |
- Eculizumab (Soliris)
- Edoxaban (Savaysa) FDA approved 1/18/2015
- Elotuzumab (Empliciti) FDA approved 11/30/2015
- Eltrombopag (Promacta)
- Emepepimut-S (Stimuvax) in clinical trials
- Encorafenib (LGX818) in clinical trials
- Entospletinib (GS-9973) in clinical trials
- Enoxaparin (Lovenox)
- Entinostat in clinical trials
- Enzalutamide (Xtandi)
- Epirubicin (Ellence)
- Epoetin alfa (Procrit)
- Epratuzumab (humanised anti-CD22 antibody) in clinical trials
- Eribulin (Halaven)
- Erlotinib (Tarceva)
- Estramustine (Emcyt)
- Etirinotecan pegol (NKTR-102) in clinical trials
- Etoposide (Vepesid)
- Everolimus (Afinitor)
- Exemestane (Aromasin)
F
| back to top |
- Factor VIIa, recombinant (NovoSeven RT)
- Factor VIII, human and recombinant (antihemophilic factor 8)
- Factor IX, human and recombinant (coagulation factor 9)
- Factor IX complex (Profilnine)
- Factor XIII concentrate, human (Corifact)
- Famciclovir (Famvir)
- Famotidine (Pepcid)
- Ferric carboxymaltose (Injectafer)
- Ferric gluconate (Ferrlecit)
- Ferrous sulfate (Feosol)
- Ferumoxytol (Feraheme)
- Fibrinogen concentrate, human (RiaSTAP)
- Filanesib (ARRY-520) in clinical trials
- Filgrastim (Neupogen)
- Filgrastim-sndz (Zarxio) FDA approved 3/6/2015
- Finasteride (Proscar)
- Fluorouracil (5-FU)
- Floxuridine (FUDR)
- Fluconazole (Diflucan)
- Fludarabine (Fludara)
- Flutamide (Eulexin)
- Folinic acid (Leucovorin)
- Fondaparinux (Arixtra)
- Forodesine (Fodosine) in clinical trials
- Fosaprepitant (Emend for Injection)
- Fostamatinib (R788) in clinical trials
- Fotemustine (Muphoran) in clinical trials
- Fulvestrant (Faslodex)
G
| back to top |
- Galeterone (TOK-001) in clinical trials
- Galunisertib (LY2157299) in clinical trials
- Ganetespib (STA-9090) in clinical trials
- Ganitumab (AMG 479) in clinical trials
- GDC-0941 in clinical trials
- Gefitinib (Iressa)
- Gemcitabine (Gemzar)
- Gemcitabine elaidate (CP-4126, CO-101) in clinical trials
- Gemtuzumab ozogamicin (Mylotarg) Discontinued
- Gilteritinib (ASP2215) in clinical trials
- Glucarpidase (Voraxaze)
- Goserelin (Zoladex)
- Granisetron (Kytril)
H
| back to top |
- Hematopoetic progenitor cells, cord blood (Hemacord)
- Heparin
- HER2 peptide vaccine (AE37) in clinical trials
- Histrelin (Vantas)
- Hydrocortisone (Cortef)
- Hydroxyurea (Hydrea)
I
| back to top |
- Ibandronate (Boniva)
- Ibritumomab tiuxetan (Zevalin)
- Ibrutinib (Imbruvica)
- Idarubicin (Idamycin)
- Idarucizumab (Praxbind) FDA approved 10/16/2015
- Idelalisib (Zydelig)
- Ifosfamide (Ifex)
- IMA901 in clinical trials
- Imatinib (Gleevec)
- Imetelstat (GRN163L) in clinical trials
- Indatuximab ravtansine (BT062) in clinical trials
- Inotuzumab ozogamicin (CMC-544) in clinical trials
- Ipilimumab (Yervoy)
- Interferon alfa-2a (Roferon-A)
- Interferon alfa-2b (Intron-A)
- IPH 2101 in clinical trials
- Irinotecan (Camptosar)
- Irinotecan liposome (Onivyde) FDA approved 10/22/2015
- Iron dextran (INFeD)
- Iron sucrose (Venofer)
- Itraconazole (Sporanox)
- Ixabepilone (Ixempra)
- Ixazomib (Ninlaro) FDA approved 11/20/2015
J
- JCAR015 in clinical trials
K
L
| back to top |
- Lactulose
- Lamivudine (Epivir)
- Lanreotide (Somatuline)
- Lansoprazole (Prevacid)
- Lapatinib (Tykerb)
- Lapuleucel-T (DN24-02) in clinical trials
- Lenalidomide (Revlimid)
- Lenograstim (Granocyte)
- Lenvatinib (Lenvima) FDA approved 2/13/2015
- Lepirudin (Refludan) discontinued
- Lestaurtinib (CEP-701) in clinical trials
- Letrozole (Femara)
- Leuprolide (Lupron)
- Levofloxacin (Levaquin)
- Levoleucovorin (Fusilev)
- LGH447 in clinical trials
- Linifanib (ABT-869) in clinical trials
- Linsitinib (OSI-906) in clinical trials
- Lipefilgrastim (XM22) in clinical trials
- Lomustine (Ceenu)
- Lorlatinib (PF-06463922) in clinical trials
- Lorvotuzumab mertansine (BB-10901) in clinical trials
M
| back to top |
- Mannitol
- Mapatumumab (HGS-ETR1) in clinical trials
- Masitinib (AB1010) in clinical trials
- Mechlorethamine (Mustargen)
- Medroxyprogesterone acetate (MPA)
- Megestrol acetate (Megace)
- Melphalan (Alkeran)
- Mepolizumab (Bosatria) in clinical trials
- Mercaptopurine (Purinethol)
- Mesna (Mesnex)
- Methotrexate (MTX)
- Methoxsalen (Uvadex)
- Methylprednisolone (Solumedrol)
- Metoclopramide (Reglan)
- Midostaurin (PKC412) in clinical trials
- Milataxel (TL139) in clinical trials
- Mirvetuximab soravtansine (IMGN853) in clinical trials
- Mitomycin (Mutamycin)
- Mitotane (Lysodren)
- Mitoxantrone (Novantrone)
- MK2206 in clinical trials
- Mocetinostat (MGCD0103) in clinical trials
- Mogamulizumab (KW-0761) in clinical trials
- Momelotinib (CYT387) in clinical trials
- Motesanib (AMG 706) in clinical trials
- Moxetumomab pasudotox (HA22) in clinical trials
- Mycophenolate mofetil (CellCept)
N
| back to top |
- Necitumumab (Portrazza) FDA approved 11/24/2015
- Nelarabine (Arranon)
- Neratinib (HKI-272) in clinical trials
- Netupitant and palonosetron (Akynzeo)
- Nilotinib (Tasigna)
- Nilutamide (Nilandron)
- Nintedanib (BIBF 1120) in clinical trials
- Nivolumab (Opdivo)
- Nolatrexed (Thymitaq)
- NovoTTF-100A system (Optune)
- NOX-A12 in clinical trials
O
| back to top |
- Obinutuzumab (Gazyva)
- Octreotide (Sandostatin)
- Octreotide LAR (Sandostatin LAR)
- Odanacatib (MK-0822) in clinical trials
- ODM-201 in clinical trials
- Ofatumumab (Arzerra)
- Olaparib (Lynparza)
- Omacetaxine (Synribo)
- Omeprazole (Prilosec)
- Ombrabulin (AVE8062) in clinical trials
- Onartuzumab (MetMAb) in clinical trials
- Ondansetron (Zofran)
- Oprelvekin (Neumega)
- Oprozomib (ONX 0912) in clinical trials
- Orteronel (TAK-700) in clinical trials
- Osimertinib (Tagrisso) FDA approved 11/13/2015
- Otlertuzumab (TRU-016) in clinical trials
- Oxaliplatin (Eloxatin)
P
| back to top |
- Paclitaxel (Taxol)
- Paclitaxel, nanoparticle albumin-bound (Abraxane)
- Pacritinib (SB1518) in clinical trials
- Palbociclib (Ibrance) FDA approved 2/3/2015
- Palonosetron (Aloxi)
- Pamidronate (Aredia)
- Panitumumab (Vectibix)
- Panobinostat (Farydak) FDA approved 2/23/2015
- Pantoprazole (Protonix)
- Pazopanib (Votrient)
- Pegaspargase (Oncaspar)
- Pegfilgrastim (Neulasta)
- Peginterferon alfa-2a (Pegasys)
- Peginterferon alfa-2b (Sylatron)
- Pembrolizumab (Keytruda)
- Pemetrexed (Alimta)
- Pentamidine (Nebupent)
- Pentostatin (Nipent)
- Pentraxin 2 (PRM-151) in clinical trials
- Perifosine (KRX-0401) in clinical trials
- Pertuzumab (Perjeta)
- Phosphomannopentaose sulfate (PI-88) in clinical trials
- Phytonadione (Vitamin K)
- Pidilizumab (CT-011) in clinical trials
- Pinatuzumab vedotin (DCDT2980S) in clinical trials
- Pirarubicin (THP)
- Pixantrone (Pixuvri)
- Plerixafor (Mozobil)
- Plicamycin (Mithracin)
- Polatuzumab vedotin (DCDS4501A) in clinical trials
- Pomalidomide (Pomalyst)
- Ponatinib (Iclusig)
- Porfimer (Photofrin)
- Pracinostat (SB939)
- Pralatrexate (Folotyn)
- Prasugrel (Effient)
- Pravastatin (Pravachol)
- Prednisone (Sterapred)
- Prednisolone (Millipred)
- Procarbazine (Matulane)
- Prochlorperazine (Compazine)
- Protamine sulfate
- Prothrombin Complex Concentrate, Human (Kcentra)
Q
- Quinine (Qualaquin)
- Quizartinib (AC220) in clinical trials
R
| back to top |
- Rabeprazole (Aciphex)
- Radium Ra 223 (Xofigo)
- Radotinib (IY5511HCL) in clinical trials
- Raloxifene (Evista)
- Raltitrexed (Tomudex)
- Ramucirumab (Cyramza)
- Ranitidine (Zantac)
- Rasburicase (Elitek)
- Regorafenib (Stivarga)
- Reovirus (Reolysin) in clinical trials
- Retaspimycin (IPI-504) in clinical trials
- Rho(D) immune globulin (RhoGAM)
- Ricolinostat (ACY-1215, Rocilinostat) in clinical trials
- Ridaforolimus (AP23573) in clinical trials
- Risedronate (Actonel)
- Rituximab (Rituxan)
- Rivaroxaban (Xarelto)
- Rociletinib (CO-1686) in clinical trials
- Rolapitant (Varubi) FDA approved 9/1/2015
- Romidepsin (Istodax)
- Romiplostim (Nplate)
- Ropeginterferon alfa-2b (AOP2014) in clinical trials
- Rucaparib (CO-338, AG-014699, PF-0136738) in clinical trials
- Ruxolitinib (Jakafi)
S
| back to top |
- Samarium-153 (Quadramet)
- Sapacitabine (CS-682) in clinical trials
- SAR650984 in clinical trials
- Sargramostim (Leukine)
- Seliciclib (CYC202) in clinical trials
- Selinexor (KPT-330) in clinical trials
- Selumetinib (AZD6244) in clinical trials
- Semuloparin (AVE5026) in clinical trials
- Sennosides (Senna)
- SGN-CD19A in clinical trials
- Siltuximab (Sylvant)
- Sipuleucel-T (Provenge)
- Sirolimus (Rapamune)
- SL-401 in clinical trials
- Sonidegib (Odomzo) FDA approved 7/24/2015
- Sorafenib (Nexavar)
- Streptozocin (Zanosar)
- Sunitinib (Sutent)
T
| back to top |
- Tacrolimus (Prograf)
- Talimogene laherparepvec (Imlygic) FDA approved on 10/27/2015
- Tamibarotene (Amnoid) in clinical trials
- Tamoxifen (Nolvadex)
- Tbo-filgrastim (Granix)
- Tegafur-uracil (UFT)
- Tegafur, gimeracil, oteracil (Teysuno, S-1) in clinical trials
- Temozolomide (Temodar)
- Temsirolimus (Torisel)
- Teniposide (Vumon)
- Tesetaxel (DJ-927) in clinical trials
- TH-302 in clinical trials
- Thalidomide (Thalomid)
- Thioguanine (Tabloid)
- Thiotepa (Thioplex)
- Ticagrelor (Brilinta)
- Tigatuzumab (CS-1008) in clinical trials
- Tinzaparin (Innohep)
- Tipifarnib (Zarnestra) in clinical trials
- Tivantinib (ARQ 197) in clinical trials
- Tivozanib (AV-951) in clinical trials
- Tocilizumab (Actemra)
- Tofacitinib (Xeljanz)
- Topotecan (Hycamtin)
- Toremifene (Fareston)
- Tosedostat (CHR-2797) in clinical trials
- Tositumomab & I-131 (Bexxar)
- Trabectedin (Yondelis)
- Trametinib (Mekinist)
- Tranexamic acid (Cyklokapron)
- Trastuzumab (Herceptin)
- Trebananib (AMG 386) in clinical trials
- Tretinoin (Vesanoid)
- Trifluridine and tipiracil (Lonsurf) FDA approved 9/22/2015
- Trimethoprim/Sulfamethoxazole (Bactrim DS)
- Triptorelin (Trelstar LA)
- Tropisetron (Navoban)
U
- Ublituximab (LFB-R603) in clinical trials
- Uridine triacetate (Vistogard) FDA approved 12/11/2015
V
| back to top |
- Valacyclovir (Valtrex)
- Valganciclovir (Valcyte)
- Valproate (Depakote)
- Valrubicin (Valstar)
- Vandetanib (Caprelsa)
- Veliparib (ABT-888) in clinical trials
- Veltuzumab (hA20) in clinical trials
- Vemurafenib (Zelboraf)
- Venetoclax (Venclexta) FDA approved 4/11/16
- Vinblastine (Velban)
- Vincristine (Oncovin)
- Vincristine liposomal (Marqibo)
- Vindesine (Eldisine)
- Vinorelbine (Navelbine)
- Vismodegib (Erivedge)
- Volasertib (BI 6727)
- Von Willebrand Factor and factor VIII complex, human
- Vorinostat (Zolinza)
- Vosaroxin (SNS 595) in clinical trials
W
| back to top |
X
- XL647 in clinical trials
- XmAb5574 (MOR00208) in clinical trials
Z
By Category
Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is still in process so not all of these links are active).
Drugs in a REMS program
Cytotoxic Chemotherapy
| back to top |
- Alkylating agents
- Anthracyclines
- Antimetabolites
- DNA synthesis inhibitors
- Microtubule inhibitors
- Nitrogen mustards
- Nitrosureas
- Platinum agents
- Proteasome inhibitors
- Taxanes
- Topoisomerase inhibitors
- Vinca alkaloids
Kinase inhibitors
| back to top |
- AKT1 inhibitors
- ALK inhibitors
- Aurora kinase inhibitors
- AXL inhibitors
- Bcr-Abl inhibitors
- BRAF inhibitors
- BTK inhibitors
- CDK inhibitors
- EGFR inhibitors
- ERBB2 inhibitors
- ERBB4 inhibitors
- FGFR inhibitors
- FLT3 inhibitors
- IGFR inhibitors
- JAK inhibitors
- KIT inhibitors
- MEK inhibitors
- MET inhibitors
- mTOR inhibitors
- PDGFR inhibitors
- PI3K inhibitors
- PLK1 inhibitors
- RET inhibitors
- ROS1 inhibitors
- SRC inhibitors
- SYK inhibitors
- TEK inhibitors
- VEGF inhibitors
Endocrine therapy
| back to top |
- Antiandrogens
- Steroid synthesis inhibitors
- Androgen receptor inhibitors
- 5 alpha-reductase inhibitors
- GnRH agonists
- GnRH antagonists
- Aromatase inhibitors
- Selective estrogen receptor modulators
- Steroids
- Somatostatin analogs
Investigational and Discontinued
Biologics
| back to top |
- Antibody medications
- Antibody-drug conjugates
- Anti-HER2 medications
- IL-6 inhibitors
- Enzymes
- Immunotherapy
- Immunomodulatory drugs (IMiDs)
Supportive Medications
| back to top |
- Antibacterials
- Antidiarrheals
- Antifungals
- Antihistamines
- Antivirals
- Bisphosphonates
- Chemotherapy protective agents
- Emesis prevention
- PCP prophylaxis
- RANK ligand inhibitors
- Steroids
Radioactive agents
Benign Hematology Medications
| back to top |
Hematopoietic Growth Factors
| back to top |
Miscellaneous
| back to top |
- HDAC inhibitors
- Hypomethylating agents
- Immunosuppresants
- Retinoids
- Vitamins
- WHO Essential Cancer Medicines
Medications by Condition
| back to top |
- Acute lymphocytic leukemia medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Anal cancer medications
- Anaplastic large cell lymphoma medications
- Basal cell and squamous cell skin cancer medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- Cancer of unknown primary medications
- Castleman’s disease medications
- Central nervous system (CNS) cancer medications
- Central nervous system (CNS) lymphoma medications
- Cervical cancer medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Chronic myelogenous leukemia medications
- Chronic myelomonocytic leukemia medications
- Colon cancer medications
- Cutaneous T-cell lymphoma medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Essential thrombocythemia medications
- Extranodal NK/T-cell lymphoma, nasal type lymphoma medications
- Follicular lymphoma medications
- Gastric cancer medications
- Hairy cell leukemia medications
- Head and neck cancer medications
- Hepatobiliary cancer medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Immune thrombocytopenic purpura (ITP) medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Melanoma medications
- Mesothelioma medications
- Multiple myeloma medications
- Myelodysplastic syndrome medications
- Myelofibrosis medications
- NK/T-cell lymphoma medications
- Non-small cell lung cancer medications
- Neuroendocrine tumor medications
- Ovarian cancer medications
- Pancreatic cancer medications
- Paroxysmal nocturnal hemoglobinuria (PNH) medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Plasma cell leukemia medications
- Polycythemia vera medications
- Primary mediastinal B-cell lymphoma medications
- Prostate cancer medications
- Rectal cancer medications
- Renal cancer medications
- Sarcoma medications
- Sickle cell anemia medications
- Small cell lung cancer medications
- T-cell lymphoma medications
- Testicular cancer medications
- Thymoma medications
- Thyroid cancer medications
- Transformed lymphoma medications
- Transplant medications
- Uterine cancer medications
- Waldenström macroglobulinemia medications
Medications by Route of Administration
| back to top |
- Intraarterial (IA) chemotherapy
- Intracavitary chemotherapy
- Intramuscular (IM) chemotherapy
- Intrathecal (IT) chemotherapy
- Intravenous (IV) chemotherapy
- Intravesicular chemotherapy
- Oral (PO) chemotherapy
- Subcutaneous (SC) chemotherapy
Medications by Year of Approval
| back to top |
- Drugs FDA approved in 1949
- Drugs FDA approved in 1951
- Drugs FDA approved in 1952
- Drugs FDA approved in 1953
- Drugs FDA approved in 1954
- Drugs FDA approved in 1955
- Drugs FDA approved in 1957
- Drugs FDA approved in 1958
- Drugs FDA approved in 1959
- Drugs FDA approved in 1962
- Drugs FDA approved in 1963
- Drugs FDA approved in 1964
- Drugs FDA approved in 1965
- Drugs FDA approved in 1966
- Drugs FDA approved in 1967
- Drugs FDA approved in 1968
- Drugs FDA approved in 1969
- Drugs FDA approved in 1970
- Drugs FDA approved in 1971
- Drugs FDA approved in 1973
- Drugs FDA approved in 1974
- Drugs FDA approved in 1975
- Drugs FDA approved in 1976
- Drugs FDA approved in 1977
- Drugs FDA approved in 1978
- Drugs FDA approved in 1979
- Drugs FDA approved in 1980
- Drugs FDA approved in 1981
- Drugs FDA approved in 1982
- Drugs FDA approved in 1983
- Drugs FDA approved in 1984
- Drugs FDA approved in 1985
- Drugs FDA approved in 1986
- Drugs FDA approved in 1987
- Drugs FDA approved in 1988
- Drugs FDA approved in 1989
- Drugs FDA approved in 1990
- Drugs FDA approved in 1991
- Drugs FDA approved in 1992
- Drugs FDA approved in 1993
- Drugs FDA approved in 1994
- Drugs FDA approved in 1995
- Drugs FDA approved in 1996
- Drugs FDA approved in 1997
- Drugs FDA approved in 1998
- Drugs FDA approved in 1999
- Drugs FDA approved in 2000
- Drugs FDA approved in 2001
- Drugs FDA approved in 2002
- Drugs FDA approved in 2003
- Drugs FDA approved in 2004
- Drugs FDA approved in 2005
- Drugs FDA approved in 2006
- Drugs FDA approved in 2007
- Drugs FDA approved in 2008
- Drugs FDA approved in 2009
- Drugs FDA approved in 2010
- Drugs FDA approved in 2011
- Drugs FDA approved in 2012
- Drugs FDA approved in 2013
- Drugs FDA approved in 2014
- Drugs FDA approved in 2015
- Drugs FDA approved in 2016
Interesting and Helpful Links
| back to top |
- Antidepressants and other psychiatric medications in cancer care
- Antiemetic support
- 2015 Update of ASCO Clinical Practice Guideline Recommendations for the Use of WBC Growth Factors[1]
- Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline (2013)
- Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline[2]
- ASCO-ONS Standards for Safe Chemotherapy Administration
- Chemotherapy Administration Sequence[3] - with chemotherapy sequencing chart
- The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. PubMed
- FDA drug shortages list
- ASHP drug shortages list - also includes information about discontinued drugs
- DailyMed - a comprehensive NLM portal to all FDA-approved drugs
- Drugs@FDA - the main portal into the FDA drug database
- The NCI Drug Dictionary - an extensive resource with most antineoplastics (approved and in clinical trials) listed
- In the Pipeline - a blog from a veteran of the pharmaceutical industry, Derek Lowe. General but much is cancer-relevant.
- Steroid conversions
- Vesicant & irritant chemotherapy
- Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers
- CPIC Guidelines The Clinical Pharmacogenetics Implementation Consortium provides guidelines for a small set of drugs with pharmacogenetically-guided dosing implications, some of which are oncologics
References
- ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13.
- ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
- ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article